Keytruda Organ Failure

Optimal Corticosteroid Therapy Based on Liver Biopsy for Severe Immune-Mediated Hepatitis During Pembrolizumab Treatment: A Case Report.

Cureus • Kichikawa Y • PMID 41808699 • Case Reports.

This case report describes a single patient who developed severe immune-mediated hepatitis while receiving pembrolizumab (Keytruda) and discusses corticosteroid treatment strategies guided by liver biopsy findings.

Severe Esophageal Ulceration With Enfortumab Vedotin Plus Pembrolizumab Therapy in Urothelial Carcinoma: A Case Report.

Anticancer research • Nakamura K • PMID 41760236 • Journal Article.

This paper describes a single case report of severe esophageal ulceration occurring in a patient receiving combination therapy with enfortumab vedotin and pembrolizumab (Keytruda) for urothelial carcinoma, attributing the adverse event to the combined treatment.

Posnick v. Merck & Co., Inc.

Federal court result for Keytruda Organ Failure: District Court, W.D. New York • 6:26-cv-06249

Immune-related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors.

British journal of haematology • Zinzani PL • PMID 41744197 • Journal Article.

This paper examines immune-related adverse events (irAEs) specifically in Hodgkin lymphoma patients treated with immune checkpoint inhibitors, describing the types and patterns of immune-related toxicities that occur with this drug class.

Resolution of vanishing bile duct syndrome in a patient associated with refractory hodgkin lymphoma following Anti-PD-1 therapy: a case report and literature review.

Annals of hematology • Huang TC • PMID 41746393 • Journal Article.

This paper describes a case where a patient with refractory Hodgkin lymphoma developed vanishing bile duct syndrome (a severe liver condition) during anti-PD-1 therapy, but then recovered after treatment discontinuation, suggesting the immune-related adverse event was linked to the checkpoint inhibitor.

Immune-Related Thyroid Dysfunction in PD-L1 High Non-Oncogene-Addicted NSCLC Treated with First-Line Pembrolizumab: Incidence, Timing, and Predictive Impact.

Current oncology (Toronto, Ont.) • Kontić M • PMID 41744872 • Journal Article.

This study examines thyroid dysfunction as an immune-related adverse event in non-small cell lung cancer patients treated with first-line pembrolizumab, tracking incidence, timing, and whether thyroid dysfunction predicts treatment response.